Cristiane Decat Bergerot1, Hannah-Rose Mitchell2, Kimlin Tam Ashing3, Youngmee Kim2. 1. Federal University of São Paulo (UNIFESP), Rua Napoleão de Barros, 754 -Vila Clementino, São Paulo, SP, 04024-002, Brazil. crisbergerot@gmail.com. 2. Department of Psychology, University of Miami, Coral Gables, FL, 33146, USA. 3. Department of Population Sciences, City of Hope Medical Center, Duarte, LA, 91010, USA.
Abstract
PURPOSE: Monitoring distress assessment in cancer patients during the treatment phase is a component of good quality care practice. Yet, there is a dearth of prospective studies examining distress. In an attempt to begin filling this gap and inform clinical practice, we conducted a prospective, longitudinal study examining changes in distress (anxiety, depression, and problems in living) by age and gender and the roles of age and gender in predicting distress. METHODS: Newly diagnosed Brazilian cancer patients (N = 548) were assessed at three time points during chemotherapy. Age and gender were identified on the first day of chemotherapy (T1); anxiety, depression, and problems in living were self-reported at T1, the planned midway point (T2), and the last day of chemotherapy (T3). RESULTS: At T1, 37 and 17% of patients reported clinically significant levels of anxiety and depression, respectively. At T3, the prevalence was reduced to 4.6% for anxiety and 5.1% for depression (p < .001). Patients 40-55 years, across all time points, reported greater anxiety and practical problems than patients >70 years (p < .03). Female patients reported greater emotional, physical, and family problems than their male counterparts (p < .04). CONCLUSIONS: For most patients, elevated levels of distress noted in the beginning of treatment subsided by the time of treatment completion. However, middle-aged and female patients continued to report heightened distress. Evidence-based psychosocial intervention offered to at risk patients during early phases of the treatment may provide distress relief and improve outcomes over the illness trajectory while preventing psychosocial and physical morbidity due to untreated chronic distress.
PURPOSE: Monitoring distress assessment in cancerpatients during the treatment phase is a component of good quality care practice. Yet, there is a dearth of prospective studies examining distress. In an attempt to begin filling this gap and inform clinical practice, we conducted a prospective, longitudinal study examining changes in distress (anxiety, depression, and problems in living) by age and gender and the roles of age and gender in predicting distress. METHODS: Newly diagnosed Brazilian cancerpatients (N = 548) were assessed at three time points during chemotherapy. Age and gender were identified on the first day of chemotherapy (T1); anxiety, depression, and problems in living were self-reported at T1, the planned midway point (T2), and the last day of chemotherapy (T3). RESULTS: At T1, 37 and 17% of patients reported clinically significant levels of anxiety and depression, respectively. At T3, the prevalence was reduced to 4.6% for anxiety and 5.1% for depression (p < .001). Patients 40-55 years, across all time points, reported greater anxiety and practical problems than patients >70 years (p < .03). Female patients reported greater emotional, physical, and family problems than their male counterparts (p < .04). CONCLUSIONS: For most patients, elevated levels of distress noted in the beginning of treatment subsided by the time of treatment completion. However, middle-aged and female patients continued to report heightened distress. Evidence-based psychosocial intervention offered to at risk patients during early phases of the treatment may provide distress relief and improve outcomes over the illness trajectory while preventing psychosocial and physical morbidity due to untreated chronic distress.
Entities:
Keywords:
Age; Anxiety; Brazilian cancer patients; Depression; Gender; Longitudinal study; Problems in living
Authors: Inge Henselmans; Vicki S Helgeson; Howard Seltman; Jakob de Vries; Robbert Sanderman; Adelita V Ranchor Journal: Health Psychol Date: 2010-03 Impact factor: 4.267
Authors: Fábio R M Santos; Elisa H Kozasa; Maria de Lourdes L F Chauffaille; Gisele W B Colleoni; Jose Roberto Leite Journal: J Psychosom Res Date: 2006-05 Impact factor: 3.006
Authors: Kate Oppegaard; Carolyn S Harris; Joosun Shin; Steven M Paul; Bruce A Cooper; Jon D Levine; Yvette P Conley; Marilyn Hammer; Frances Cartwright; Fay Wright; Laura Dunn; Kord M Kober; Christine Miaskowski Journal: Support Care Cancer Date: 2021-06-26 Impact factor: 3.603
Authors: Patricia I Jewett; Deanna Teoh; Sue Petzel; Heewon Lee; Audrey Messelt; Jeffrey Kendall; Dorothy Hatsukami; Susan A Everson-Rose; Anne H Blaes; Rachel I Vogel Journal: JCO Oncol Pract Date: 2020-02-24
Authors: Zev M Nakamura; Allison M Deal; Kirsten A Nyrop; Yi Tang Chen; Laura J Quillen; Tucker Brenizer; Hyman B Muss Journal: Oncologist Date: 2020-10-02 Impact factor: 5.837
Authors: Angelo Braga Mendonça; Eliane Ramos Pereira; Carinne Magnago; Pedro Gilson da Silva; Diva Cristina Morett Leão; Rose Mary Costa Rosa Andrade Silva; Karina Cardoso Meira Journal: Int J Environ Res Public Health Date: 2021-12-15 Impact factor: 3.390